Scarica l'app Stockscreener
8.18
3.31%
-0.28
Dopo l'orario di chiusura:
8.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Precedente Chiudi:
$8.46
Aprire:
$8.35
Volume 24 ore:
1.57M
Relative Volume:
0.75
Capitalizzazione di mercato:
$1.42B
Reddito:
$25.55M
Utile/perdita netta:
$-341.97M
Rapporto P/E:
-2.9214
EPS:
-2.8
Flusso di cassa netto:
$-304.44M
1 W Prestazione:
-4.44%
1M Prestazione:
+9.21%
6M Prestazione:
+127.22%
1 anno Prestazione:
+90.23%
Intervallo 1D:
$8.06
$8.55
Intervallo di 1 settimana:
$8.06
$8.58
Portata 52W:
$1.775
$9.04
Relay Therapeutics Inc Stock (RLAY) Company Profile
Nome
Relay Therapeutics Inc
Settore
Industria
Telefono
617-370-8837
Indirizzo
60 HAMPSHIRE STREET, CAMBRIDGE
Confronta RLAY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
8.18 | 1.47B | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-04-17 | Iniziato | Wells Fargo | Equal Weight |
| 2024-09-10 | Ripresa | Goldman | Buy |
| 2024-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-04-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Iniziato | Raymond James | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-09-30 | Iniziato | Barclays | Equal Weight |
| 2022-09-02 | Iniziato | Stifel | Buy |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-02-01 | Iniziato | Berenberg | Buy |
| 2021-07-21 | Iniziato | BofA Securities | Buy |
| 2020-12-15 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-11-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-10 | Iniziato | Cowen | Outperform |
| 2020-08-10 | Iniziato | Goldman | Buy |
| 2020-08-10 | Iniziato | Guggenheim | Buy |
| 2020-08-10 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week - MSN
Aug Action: What makes Relay Therapeutics Inc. stock attractive to growth fundsPortfolio Value Report & Weekly High Conviction Trade Ideas - moha.gov.vn
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Take Profit: Can Relay Therapeutics Inc. stock hit record highs again2025 Valuation Update & Precise Trade Entry Recommendations - moha.gov.vn
Will Relay Therapeutics Inc. stock gain from strong economyFibonacci Retracement Levels & Analyze Your Portfolio Risk in Seconds - bollywoodhelpline.com
Relay Therapeutics (NASDAQ:RLAY) Shares Up 4.9%Here's What Happened - MarketBeat
Congress Asset Management Co. Has $2.13 Million Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics signals slowdown to recharge after busy year - Traders Union
Will Relay Therapeutics Inc stock pay special dividendsMarket Sentiment Report & Verified Technical Signals - moha.gov.vn
Zovegalisib’s Consistent Efficacy Across Tough Subgroups Could Be A Game Changer For Relay (RLAY) - simplywall.st
What sentiment indicators say about Relay Therapeutics Inc. stockQuarterly Market Summary & High Win Rate Trade Alerts - Улправда
Can Relay Therapeutics Inc. stock hit analyst price targets2025 Sector Review & AI Enhanced Trading Alerts - Улправда
Sectors Review: Is Relay Therapeutics Inc. stock a buy before product launchesJuly 2025 Decliners & Verified Entry Point Detection - Улправда
Why Relay Therapeutics Inc. stock could outperform in 2025Quarterly Portfolio Summary & Consistent Growth Stock Picks - Улправда
Is Relay Therapeutics Inc. stock a buy before product launchesJuly 2025 News Drivers & Low Drawdown Trading Strategies - Улправда
Is Relay Therapeutics Inc. stock attractive for passive investors2025 Biggest Moves & Risk Managed Investment Entry Signals - Улправда
Can Relay Therapeutics Inc. stock resist market sell offsPortfolio Return Report & Low Risk High Reward Ideas - DonanımHaber
Can Relay Therapeutics Inc. stock hit record highs againTake Profit & High Conviction Buy Zone Picks - DonanımHaber
How Relay Therapeutics Inc. stock reacts to oil pricesTrade Performance Summary & Daily Profit Focused Stock Screening - Улправда
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares - AOL.com
Alert from Equity-Insider.com was published in error and has been withdrawn - marketscreener.com
Relay Therapeutics (NASDAQ:RLAY) Trading Up 4.7%Here's What Happened - MarketBeat
Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 - Yahoo Finance
Will Broad Zovegalisib Breast Cancer Data Reshape Relay Therapeutics' (RLAY) Targeted Oncology Narrative? - Yahoo Finance
Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year HighStill a Buy? - MarketBeat
Bellevue Group AG Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics stock hits 52-week high at 8.62 USD By Investing.com - Investing.com Australia
Wells Fargo Upgrades Relay Therapeutics (RLAY) - Nasdaq
Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug - Sahm
Why Is Relay Therapeutics Stock Gaining Friday?Relay Therapeutics (NASDAQ:RLAY) - Benzinga
RLAY Stock Receives Analyst Upgrade and Price Target Boost | RLA - GuruFocus
Relay Therapeutics stock hits 52-week high at 8.62 USD - Investing.com India
Relay Therapeutics Reports 'Robust Activity' in Study of Zovegalisib to Treat Breast Cancer - marketscreener.com
Relay Therapeutics (RLAY) Shares New Data from Zovegalisib Study - GuruFocus
Relay Therapeutics unveils efficacy subset analysis for zovegalisib at SABCS25 - Traders Union
Relay Therapeutics Reports Positive Efficacy Data for Zovegalisib in Metastatic Breast Cancer at SABCS 2025 - Quiver Quantitative
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 - Yahoo Finance
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat
149,701 Shares in Relay Therapeutics, Inc. $RLAY Acquired by HighVista Strategies LLC - MarketBeat
Here's Why Relay Therapeutics, Inc. (RLAY) is a Great Momentum Stock to Buy - MSN
Norges Bank Buys Shares of 835,874 Relay Therapeutics, Inc. $RLAY - MarketBeat
Diadema Partners LP Has $151,000 Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Mixed Investor Sentiment Surrounds Relay Therapeutics Stock - AD HOC NEWS
Growth Value: Why Relay Therapeutics Inc stock could outperform in 20252025 Market Trends & Technical Pattern Recognition Alerts - moha.gov.vn
JPMorgan Chase & Co. Reduces Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Down 5%What's Next? - MarketBeat
Relay Therapeutics, Inc. $RLAY Position Lifted by Franklin Resources Inc. - MarketBeat
Is Relay Therapeutics Inc. stock gaining market shareJuly 2025 Rallies & Low Drawdown Investment Strategies - Newser
Relay Therapeutics, Inc. $RLAY Shares Bought by Geode Capital Management LLC - MarketBeat
Relay Therapeutics Inc Azioni (RLAY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):